Plain-English translation of NCT05707819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing Sintilimab, a medication that helps your immune system fight cancer, combined with chemotherapy and radiation therapy for people with advanced nasopharyngeal cancer (cancer in the upper part of the throat behind the nose). You would receive the medication alongside chemotherapy before radiation, and then continue the medication alone for several months after radiation therapy ends. Researchers want to see if adding this immune-boosting treatment improves outcomes for people with this serious type of cancer.
Advanced nasopharyngeal cancer is difficult to treat and many patients don't survive long-term with standard chemotherapy and radiation alone. This medication is designed to wake up your immune system so it can better recognize and destroy cancer cells, and researchers believe combining it with traditional treatments might help more patients survive and stay cancer-free.
You likely qualify if…
You likely don't qualify if…
You would start the medication at the same time you begin three cycles of chemotherapy (about 9 weeks). During this time, you would also receive radiation therapy delivered in 33 daily sessions over about 6.5 weeks. After radiation ends, you would continue receiving the medication alone every 3 weeks for about 11 more months (11 additional doses). In total, you would receive the immune-boosting medication for about 17 doses over roughly one year, with regular clinic visits for blood tests, imaging scans, and check-ins to monitor how you're tolerating treatment.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Sponsor
Cancer Hospital of Guangxi Medical University
Enrollment target
~43 participants
Started
July 2022
Primary completion
December 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in February 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiao-Dong Zhu, Doctor
Cancer Hospital of Guangxi Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.